Global Research PartnershipsCreate free account
Industry Collaboration Index

Industry Collaboration Index 2026 · University profile

Andalas University

Indonesia · Asia-Pacific · Not yet ranked

27Verified industry works, 2021 to 2025
17Company groups worked with (4 on two or more works)
100Verified works needed for a ranking

Andalas University is not yet ranked: it has 27 verified industry works in 2021 to 2025, below the 100 a reliable score needs.

Research Collaboration Index 2026: #1181 of 1,195 · View the RCI profile →

Not yet ranked. Andalas University has 27 verified industry co-authored works in 2021 to 2025, below the 100 needed for a reliable score. The evidence found so far is shown below.
0.2%of its 14,176 research works in 2021 to 2025 were co-authored with a verified company
0.08times the industry co-authorship rate expected for its mix of research fields (27 verified works; about 338 expected)

Where it works with industry

Sector strengths

Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.

Not yet ranked in any sector: a sector ranking needs at least 20 verified works in the sector. Its largest sector is Medical Technology and Digital Health, with 2.

Medical Technology and Digital Health
2under 20 works
Advanced Materials and Nanotechnology
1under 20 works
Automotive and Mobility
1under 20 works
Chemicals, Process and Resources
0.5under 20 works
Not in any of the 21 sectors
22.5counted in the overall index

4.5 of its 27 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.

Who it works with

Company partners, 2021 to 2025

Andalas University co-authored verified work with 17 company groups, consortium papers aside: 4 of them on two or more works.

The largest 12 of its 17 company groups, by joint works

Company groupBased inCompany's main research fieldJoint worksYears with a joint work
PertaminaSTATE-OWNEDIndonesiaEngineering53 of 5
Siemens HealthineersGermanyMedicine22 of 5
CareDxUnited StatesMedicine22 of 5
PT Bio FarmaIndonesiaMedicine21 of 5
Blue IndustriesJapanNot recorded11 of 5
KarsaFinlandMedicine11 of 5
Merck & Co. (MSD)United StatesMedicine11 of 5
IntelUnited StatesEngineering11 of 5
Philip Morris InternationalSwitzerlandBiochemistry, Genetics and Molecular Biology11 of 5
PT Dexa MedicaIndonesiaBiochemistry, Genetics and Molecular Biology11 of 5
DNASTARUnited StatesBiochemistry, Genetics and Molecular Biology11 of 5
SyngentaSTATE-OWNEDSwitzerlandMedicine11 of 5

A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.

Examples of its work with industry

Most-cited verified joint works

Over time

Verified industry works by year

02021
7.52022
7.52023
62024
62025

2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.

Clinical trials (reported, not scored)

3 industry-partnered clinical trials

Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.

Examples:

  • NCT05546502 Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children with PT Bio Farma, 2022
  • NCT05433285 Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine with PT Bio Farma, 2022
  • NCT05313035 Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine with PT Bio Farma, 2022

Evidence checked

30 verified company links

Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 159 of 189 candidate links were set aside.

Why links were set aside
  • 132 company name not written in the author's affiliation
  • 13 a place or common word that failed its stricter rule
  • 5 part of a university or public institute's own unit
  • 5 ordinary-word name without a company suffix
  • 2 part of a street or district address
  • 2 refresh_university_not_on_work

If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.

GRP Partnership Intelligence Platform

Where Andalas University's collaboration could go next

This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.

Request first access →  See what is inside →

The platform cannot move any university's position, band or score.

The other GRP index

Research Collaboration Index

In the Research Collaboration Index 2026, Andalas University ranks #1181 of 1,195. It measures the whole research network, not only industry.

View the RCI profile →

Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.